Fintech PR
Emirates Medical Group and Bee’ah Conduct High-level Talks With the Department of Health and Social Care in the UK to Bring World-class Healthcare Solutions to the UAE
Reading Time: 3 minutes
His Excellency Salim bin Mohamed Al Owais, chairman of the board of directors of Bee’ah; the Middle East’s sustainability pioneer and the Emirates Medical Group concluded a visit with Baroness Nicola Blackwood, Minister at the Department of Health and Social Care on 14th May 2019 where they took part in key healthcare cooperation talks towards bringing the latest in the UK’s recognized expertise and best practices in healthcare to the United Arab Emirates (UAE).
The newly launched Emirates Medical Group, an innovative healthcare services organization headquartered in the emirate of Sharjah in the UAE, led by H.E Salim bin Mohamed Al Owais, met with Baroness Blackwood who was appointed as a Parliamentary Under-Secretary of State at the Department of Health and Social Care on 10 January 2019. The official delegation accompanying Al Owais included H.E Khaled Al Huriamel, Group CEO of Bee’ah and other senior executives.
Together, Emirates Medical Group and Bee’ah are exploring multiple avenues of cooperation and potential partnerships with the UK in the field of healthcare to open up channels of investment in medical projects, exchange expertise and further advance the quality of healthcare in compliance with best practice international standards.
The Emirates Medical Group is driven by a mission to provide and deliver an integrated healthcare solution for the emirate of Sharjah and the UAE, covering a diverse and fully-rounded spectrum of traditional and smart medical services. This includes hospitals, clinics, pharmacies, homecare, telemedicine and research centers covering every aspect of patients’ journey and medical cycle across prevention, treatment and recovery.
This has sparked interest from leading international health organizations around the world, with the UK showing a real keenness to bring the best that the UK healthcare sector has to offer to the UAE and Sharjah through this potential partnership.
Commenting on the visit, H.E Salim bin Mohamed Al Owais, Chairman of Bee’ah and the Emirates Medical Group stated, “We are extremely proud to support Sharjah’s visionary plans under the leadership of His Higness Sheikh Dr. Sultan bin Muhammad al Qasimi, Supreme Council Member and Ruler of Sharjah and Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, wife of His Highness The Ruler of Sharjah, as their continual guidance and involvement in effectively enhancing the quality of life and health has advanced social work, culture, philanthropy and business on multiple strategic levels. The initial talks with the UK’s Department of Health and Social Care aims to fulfil the aspirations and directives of our wise leadership by elevating standards and creating a world-class healthcare sector that will set new benchmarks in Sharjah and the UAE in line with vital sector transformation plans.”
Al Owais added, “These efforts aim to assist with improving the quality of lives for individuals and communities, and we are confident that citizens of Sharjah and the UAE will greatly benefit from the world-renowned expertise of the UK in the healthcare sector.”
Al Owais went on to say that the Bee’ah Group reflects its vision to provide a sustainable quality of life in the region by pursuing innovative synergies between sustainability and digitization as they are considered two mutually inclusive pillars of a robust modern economy and serve as guidelines that are deeply ingrained in all of the organization’s operations and activities. This is also embodied in our new headquarters building that will be completed this year, while leveraging an “office of the future” artificial intelligence platform to make it one of the smartest and most sustainable office buildings in the world.
Simon Penney, Her Majesty’s Trade Commissioner for the Middle East, commented on potential partnerships with UK healthcare organizations and stated: “We are delighted that Emirates Medical Group and Bee’ah are exploring potential healthcare partnerships with the UK. The UK and the UAE share a common goal of delivering the highest-quality medical care for our respective populations, using innovation to tackle some of the greatest healthcare challenges of our time, from diabetes to chronic disease. The UK is blessed with outstanding research and development in world-class universities; seventy years of medical expertise in the National Health Service; and strong capability in biotech and digital health. We are keen to collaborate with our partners in the UAE and wider region to exchange expertise and deliver the highest standards of care for all our people.”
In recent years, Bee’ah has successfully launched a number of unique healthcare-related solutions that aim to safeguard the public’s well-being and interests through consumer protection offerings that leverage innovative digitization to better serve the evolving needs of communities across Sharjah and the UAE. Bee’ah has contributed towards the minimization of counterfeit medicines in the UAE through a unique track-and-trace application, Smart Track. Developed by Evoteq, the company’s digital arm, Smart Track is an advanced serialization and tracing system, that has linked and developed new generation technology to track and trace GS1 serialized pharmaceutical products from the point of production to the end-user.
SOURCE Bee’ah
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News7 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News7 days ago
Global Airlines Appoints New Head of Finance from KPMG
-
Latest News6 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News7 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News4 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News7 days ago
IMC Pan Asia Alliance Is Now Known as Tsao Pao Chee Group
-
Latest News4 days ago
BII and FMO back BECIS with joint US$50 million financing facility supporting commercial and industrial renewables sector in South-East Asia
-
Latest News4 days ago
Banxso Acquires Australian ASIC License, Enhancing Its Global Trading Operations